Citation

Aditya H. Gaur, Kristin Baltrusaitis, Edmund V. Capparelli, John H. Moye, Dwight E. Yin, Gaerolwe Masheto, Sarah Buisson, Conn M. Harrington, Mark A. Marzinke, Elizabeth D. Lowenthal, Rachel Scheckter, Andi Ace, Shawn Ward, Ryan Milligan, Kyle Whitson, Jenny Huang, S. Y. Amy Cheung, Brookie M. Best, Ellen Townley, Gilly Roberts, Thomas Kakuda, Eileen Birmingham, Sisinyana Ruth Mathiba, Linda Aurpibul, Violet Korutaro, Christiana Smith, Faeezah Patel, Evette Moodley, Carolyn Bolton Moore, IMPAACT 2017 Collaborators, IMPAACT 2017 Team. Safety, antiviral activity and pharmacokinetics of open-label long-acting cabotegravir + rilpivirine in the first study of virologically suppressed adolescents living with HIV-1 to receive an every 8-week, all-injectable regimen in a multicenter, multinational single-arm study: IMPAACT 2017 Week-48 Outcomes. Lancet HIV. 2026.

Citation

Elizabeth D. Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, Grace Kovic, Sanjna Merchant, Kaleb Branch, Chermiqua Tsosie, Martina Zapata Vaca, Barbara Heckman, Rodica Van Solingen-Ristea, Conn M. Harrington, Dwight E. Yin, Ellen Townley, Michael Whitton, Allison L. Agwu, Christiana Smith, Mary E. Paul, Avy Violari, Evette Moodley, Maxensia Owor, Kulkanya Chokephaibulkit, Samantha Fry, Jennifer Jao, Charles D. Mitchell, Sarah Buisson, Andi Ace, Irina Kolobova, Carolyn Bolton Moore, Aditya H. Gaur, IMPAACT 2017 Collaborators, IMPAACT 2017 Team. Acceptability and tolerability of long-acting injectable cabotegravir plus rilpivirine across the first 48 weeks of treatment in adolescents living with HIV: results from the More Options for Children and Adolescents (IMPAACT 2017/ MOCHA) phase I/II trial. Lancet HIV. 2026.